title: The dose of granulocyte-colony-stimulating factor after chemopriming treatment does not influence apheresis yield of progenitor cells: a retrospective study of 91 cases.
abstract: BACKGROUND
  The optimal dose of post-chemotherapy granulocyte-colony-stimulating factor (G-CSF) administration before peripheral blood progenitor cell (PBPC) collection has not been determined as yet, although 5 microg per kg per day has been recommended as the standard dose. This study retrospectively analyzed the effect of G-CSF dose on peripheral blood CD34+ cell collection from 91 patients with hematologic malignancies.
  
  
  METHODS
  Various doses of G-CSF were administered after several chemotherapeutic PBPC mobilization regimens. According to the dose of G-CSF administered, patients were assigned to two groups. Group 1 included 46 patients who received a low dose of G-CSF (median, 3.6 [range, 2.8-4.6] microg/kg/day). Group 2 included 45 patients who received a standard G-CSF dose of 6.0 (5.5-8. 1) microg per kg per day. Patients in the two groups were matched for age, diagnosis, previous therapy, and chemotherapeutic PBPC mobilization regimens.
  
  
  RESULTS
  No difference was observed in the median number of CD34+ cells harvested from each group. The number of leukapheresis procedures necessary to obtain a minimum of 3 x 10(6) CD34+ cells per kg was the same in both groups, and the percentage of patients who failed to achieve adequate PBPC collections was similar in the two groups.
  
  
  CONCLUSIONS
  The administration of low-dose G-CSF after chemotherapy appears equivalent to administration of the standard dose in achieving satisfactory PBPC collection. This approach could allow significant savings in medical cost. A randomized and prospective study is necessary, however, to assess the validity of these conclusions.
authors.affiliation: Department of Adult Hematology and the Blood Bank Center, Necker Hospital, Paris, France. bruno.varet@nck.ap-hop-paris.fr
authors.forename: F
authors.initials: F
authors.lastname: Lefrère
authors.forename: C
authors.initials: C
authors.lastname: Belanger
authors.forename: F
authors.initials: F
authors.lastname: Audat
authors.forename: O
authors.initials: O
authors.lastname: Hermine
authors.forename: M
authors.initials: M
authors.lastname: Cavazzana-Calvo
authors.forename: B
authors.initials: B
authors.lastname: Arnulf
authors.forename: A
authors.initials: A
authors.lastname: Buzyn
authors.forename: B
authors.initials: B
authors.lastname: Varet
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000097:blood; D001772:Blood Cell Count / Q000187:drug effects; D001800:Blood Specimen Collection; D001804:Blood Transfusion, Autologous; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000628:therapy; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013234:Stem Cells / Q000276:immunology
chemical_list: D018952:Antigens, CD34; D016179:Granulocyte Colony-Stimulating Factor